Actuate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACTU Nasdaq 2834 actuatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actuate Therapeutics, Inc.

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - Dec 15th, 2025 6:45 am
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Nov 28th, 2025 7:55 am
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation - Nov 15th, 2025 5:00 am
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - Sep 22nd, 2025 6:45 am
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option - Sep 11th, 2025 2:01 pm
Sector Update: Health Care Stocks Retreat Late Afternoon - Sep 10th, 2025 1:52 pm
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - Sep 10th, 2025 6:31 am
Actuate Therapeutics Announces Proposed Public Offering of Common Stock - Sep 9th, 2025 2:07 pm
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy - Aug 25th, 2025 8:00 am
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20% - Aug 15th, 2025 4:28 am
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - Aug 6th, 2025 6:45 am
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas - Jul 17th, 2025 6:45 am
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial - Jun 24th, 2025 7:15 am
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - Jun 20th, 2025 6:45 am
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Jun 16th, 2025 6:30 am
Actuate Therapeutics shares highlights from KOL eventon elraglusib data - Jun 3rd, 2025 7:15 am
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - Jun 2nd, 2025 7:00 am
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - May 31st, 2025 2:30 pm
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - May 22nd, 2025 3:05 pm
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting - May 7th, 2025 6:00 am